SpectrumX, the currently privately held biotech company based in the UK, says it could well IPO in the New Year. The company is known for its HOCl-based healthcare products, including Spectricept, for which it controls and license and patent for UK and Europe.
Naturally produced by our white blood cells, HOCl is an essential part of the body’s immune system with the potential to eradicate bacteria, mycobacterium, spores, fungi, viruses – within seconds. Traditional HOCl products and manufacturing are highly susceptible to degradation and therefore not as reliable compared to other biocide disinfection solutions.
Ahead of IPO, SpectrumX management told investors this month that the company was looking at a £5-10m institutional raise at a £120m valuation (likely EIS/VCT) in 1H25. This would allow further business development and investment in a large scale pharmaceutical manufacturing line, moving SpectrumX firmly into the “mid pharma” category with regards to capacity.
Management recently told investors that they would be monitoring the IPO market in the first half of 2025, with a potential view to a listing.
What is giving Spectrum X the edge in the biotech stakes?
Want the full story? Access all of The Armchair Trader's content for just £5.99 per month.
Get weekly investment ideas and tips that will take your investing to the next level. Sign up here.
Free 28 day trial. Cancel anytime.
Log In or Sign Up to Armchair Trader+Already a member? Log in here:
Not a member? Sign up now or see the membership benefits
Further content of this article is not available as it is for members only. Please visit the registration page for Armchair Trader Plus+ for further details on the benefits of becoming a member.
